Hypoparathyroidism historical perspective: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
m (Bot: Removing from Primary care) |
||
| (19 intermediate revisions by 2 users not shown) | |||
| Line 2: | Line 2: | ||
{{Hypoparathyroidism}} | {{Hypoparathyroidism}} | ||
{{CMG}}; {{AE}} {{ | {{CMG}}; {{AE}} {{Anmol}} | ||
==Overview== | ==Overview== | ||
In 1909, William George MacCallum and Carl Voegtlin, demonstrated association between [[parathyroid gland]], [[calcium]], and [[tetany]]. In 1959, Howard Rasmussen and Lyman C. Craig at the Rockefeller Institute for Medical Research purified [[parathyroid hormone]]. In 1925, James Bertram Collip along with Douglous B Leitch treated [[tetany]] with the help of [[Parathyroid gland|parathyroid]] extract. In 2015, use of recombinant human [[parathyroid hormone]] 1-84 (rhPTH 1-84) for the management of hypoparathyroidism was approved by the U.S. [[Food and Drug Administration]] ([[FDA]]). | |||
==Historical Perspective== | ==Historical Perspective== | ||
===Discovery=== | ===Discovery=== | ||
*[ | * In 1852, Sir Richard Owen, Hunterian Professor and Conservator of the Museum in the Royal College of Surgeons of England, described [[parathyroids]] in rhinoceros.<ref name="pmid15459265">{{cite journal |vauthors=Modarai B, Sawyer A, Ellis H |title=The glands of Owen |journal=J R Soc Med |volume=97 |issue=10 |pages=494–5 |year=2004 |pmid=15459265 |pmc=1079622 |doi=10.1258/jrsm.97.10.494 |url=}}</ref> | ||
* In 1880, Ivar Sandström, a Swedish [[anatomist]], described [[parathyroids]] in human following 50 autopsies. He found two [[parathyroid]] glands bilaterally in 43 out of 50 [[autopsies]].<ref name="pmid25913489">{{cite journal |vauthors=Johansson H |title=The Uppsala anatomist Ivar Sandström and the parathyroid gland |journal=Ups. J. Med. Sci. |volume=120 |issue=2 |pages=72–7 |year=2015 |pmid=25913489 |pmc=4463479 |doi=10.3109/03009734.2015.1027426 |url=}}</ref> | |||
* | * In 1909, William George MacCallum and Carl Voegtlin, demonstrated association between [[parathyroid gland]], [[calcium]], and [[tetany]].<ref name="pmid19867238">{{cite journal |vauthors=Maccallum WG, Voegtlin C |title=ON THE RELATION OF TETANY TO THE PARATHYROID GLANDS AND TO CALCIUM METABOLISM |journal=J. Exp. Med. |volume=11 |issue=1 |pages=118–51 |year=1909 |pmid=19867238 |pmc=2124703 |doi= |url=}}</ref> | ||
*In [ | * In 1942, Albright et. al. first described the term [[pseudohypoparathyroidism]]. It is an example of Seabright-Bantam syndrome. In [[pseudohypoparathyroidism]] [[hypocalcemia]] and [[hyperphosphatemia]] is resistant to [[parathyroid hormone]] administration.<ref>{{cite journal |vauthors=Albright F, Burnett CH, Smith PH, Parson |date=1942 |title=Pseudohypoparathyroidism- An example of ‘Seabright-Bantam syndrome’ |url= |journal= Endocrinology |volume=30 |issue= |pages=922–32 |doi= |access-date= }}</ref> | ||
*In [year] | * In 1959, Howard Rasmussen and Lyman C. Craig at the Rockefeller Institute for Medical Research purified [[parathyroid hormone]].<ref name="RasmussenCraig1959">{{cite journal|last1=Rasmussen|first1=Howard|last2=Craig|first2=Lyman C.|title=PURIFICATION OF PARATHYROID HORMONE BY USE OF COUNTERCURRENT DISTRIBUTION|journal=Journal of the American Chemical Society|volume=81|issue=18|year=1959|pages=5003–5003|issn=0002-7863|doi=10.1021/ja01527a066}}</ref> They also isolated the active [[polypeptide]] (parathormone B) from bovine [[parathyroid gland]] and gave its tentative formula in 1961.<ref>{{Cite journal||last1=Rasmussen|first1=Howard|last2=Craig|first2=Lyman C.|title = Isolation of a Parathyroid Polypeptide from Acetic Acid Extracts of Bovine Parathyroid Glands|volume = 236| number = 4|pages = 1083-1086|year = 1961|URL = http://www.jbc.org/content/236/4/1083.short|journal = {Journal of Biological Chemistry}}</ref> | ||
== | |||
==Landmark Events in the Development of Treatment Strategies== | ==Landmark Events in the Development of Treatment Strategies== | ||
*In [year], [ | *In 1925, James Bertram Collip along with Douglous B Leitch treated [[tetany]] with the help of [[Parathyroid gland|parathyroid]] extract. They names the extract as parathyrin.<ref name="pmid20315252">{{cite journal |vauthors=Collip JB, Leitch DB |title=A Case of Tetany treated with Parathyrin |journal=Can Med Assoc J |volume=15 |issue=1 |pages=59–60 |year=1925 |pmid=20315252 |pmc=1707993 |doi= |url=}}</ref> | ||
*In 1996, Winer and collegues demonstrated a reduction in [[urinary]] [[calcium]] excretion in patients of hypoparathyroidism when treated with PTH 1-34 ([[teriparatide]]) when compared with treatment with [[calcitriol]] and [[calcium]].<ref name="pmid8773636">{{cite journal |vauthors=Winer KK, Yanovski JA, Cutler GB |title=Synthetic human parathyroid hormone 1-34 vs calcitriol and calcium in the treatment of hypoparathyroidism |journal=JAMA |volume=276 |issue=8 |pages=631–6 |year=1996 |pmid=8773636 |doi= |url=}}</ref> | |||
== | *In 2015, use of recombinant human [[parathyroid hormone]] 1-84 (rhPTH 1-84) for the management of hypoparathyroidism was approved by the U.S. [[Food and Drug Administration]] ([[Food and Drug Administration|FDA]]).<ref name="pmid26938200">{{cite journal |vauthors=Bilezikian JP, Brandi ML, Cusano NE, Mannstadt M, Rejnmark L, Rizzoli R, Rubin MR, Winer KK, Liberman UA, Potts JT |title=Management of Hypoparathyroidism: Present and Future |journal=J. Clin. Endocrinol. Metab. |volume=101 |issue=6 |pages=2313–24 |year=2016 |pmid=26938200 |pmc=5393596 |doi=10.1210/jc.2015-3910 |url=https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125511s000lbl.pdf}}</ref> | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
| Line 31: | Line 25: | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
[[Category:Disease]] | |||
[[Category:Medicine]] | |||
[[Category:Endocrinology]] | |||
[[Category:Parathyroid disorders]] | |||
[[Category:Up-To-Date]] | |||
Latest revision as of 22:18, 29 July 2020
|
Hypoparathyroidism Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Hypoparathyroidism historical perspective On the Web |
|
American Roentgen Ray Society Images of Hypoparathyroidism historical perspective |
|
Risk calculators and risk factors for Hypoparathyroidism historical perspective |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Anmol Pitliya, M.B.B.S. M.D.[2]
Overview
In 1909, William George MacCallum and Carl Voegtlin, demonstrated association between parathyroid gland, calcium, and tetany. In 1959, Howard Rasmussen and Lyman C. Craig at the Rockefeller Institute for Medical Research purified parathyroid hormone. In 1925, James Bertram Collip along with Douglous B Leitch treated tetany with the help of parathyroid extract. In 2015, use of recombinant human parathyroid hormone 1-84 (rhPTH 1-84) for the management of hypoparathyroidism was approved by the U.S. Food and Drug Administration (FDA).
Historical Perspective
Discovery
- In 1852, Sir Richard Owen, Hunterian Professor and Conservator of the Museum in the Royal College of Surgeons of England, described parathyroids in rhinoceros.[1]
- In 1880, Ivar Sandström, a Swedish anatomist, described parathyroids in human following 50 autopsies. He found two parathyroid glands bilaterally in 43 out of 50 autopsies.[2]
- In 1909, William George MacCallum and Carl Voegtlin, demonstrated association between parathyroid gland, calcium, and tetany.[3]
- In 1942, Albright et. al. first described the term pseudohypoparathyroidism. It is an example of Seabright-Bantam syndrome. In pseudohypoparathyroidism hypocalcemia and hyperphosphatemia is resistant to parathyroid hormone administration.[4]
- In 1959, Howard Rasmussen and Lyman C. Craig at the Rockefeller Institute for Medical Research purified parathyroid hormone.[5] They also isolated the active polypeptide (parathormone B) from bovine parathyroid gland and gave its tentative formula in 1961.[6]
Landmark Events in the Development of Treatment Strategies
- In 1925, James Bertram Collip along with Douglous B Leitch treated tetany with the help of parathyroid extract. They names the extract as parathyrin.[7]
- In 1996, Winer and collegues demonstrated a reduction in urinary calcium excretion in patients of hypoparathyroidism when treated with PTH 1-34 (teriparatide) when compared with treatment with calcitriol and calcium.[8]
- In 2015, use of recombinant human parathyroid hormone 1-84 (rhPTH 1-84) for the management of hypoparathyroidism was approved by the U.S. Food and Drug Administration (FDA).[9]
References
- ↑ Modarai B, Sawyer A, Ellis H (2004). "The glands of Owen". J R Soc Med. 97 (10): 494–5. doi:10.1258/jrsm.97.10.494. PMC 1079622. PMID 15459265.
- ↑ Johansson H (2015). "The Uppsala anatomist Ivar Sandström and the parathyroid gland". Ups. J. Med. Sci. 120 (2): 72–7. doi:10.3109/03009734.2015.1027426. PMC 4463479. PMID 25913489.
- ↑ Maccallum WG, Voegtlin C (1909). "ON THE RELATION OF TETANY TO THE PARATHYROID GLANDS AND TO CALCIUM METABOLISM". J. Exp. Med. 11 (1): 118–51. PMC 2124703. PMID 19867238.
- ↑ Albright F, Burnett CH, Smith PH, Parson (1942). "Pseudohypoparathyroidism- An example of 'Seabright-Bantam syndrome'". Endocrinology. 30: 922–32.
- ↑ Rasmussen, Howard; Craig, Lyman C. (1959). "PURIFICATION OF PARATHYROID HORMONE BY USE OF COUNTERCURRENT DISTRIBUTION". Journal of the American Chemical Society. 81 (18): 5003–5003. doi:10.1021/ja01527a066. ISSN 0002-7863.
- ↑ Rasmussen, Howard; Craig, Lyman C. (1961). "Isolation of a Parathyroid Polypeptide from Acetic Acid Extracts of Bovine Parathyroid Glands". {Journal of Biological Chemistry. 236 (4): 1083–1086.
- ↑ Collip JB, Leitch DB (1925). "A Case of Tetany treated with Parathyrin". Can Med Assoc J. 15 (1): 59–60. PMC 1707993. PMID 20315252.
- ↑ Winer KK, Yanovski JA, Cutler GB (1996). "Synthetic human parathyroid hormone 1-34 vs calcitriol and calcium in the treatment of hypoparathyroidism". JAMA. 276 (8): 631–6. PMID 8773636.
- ↑ Bilezikian JP, Brandi ML, Cusano NE, Mannstadt M, Rejnmark L, Rizzoli R, Rubin MR, Winer KK, Liberman UA, Potts JT (2016). "Management of Hypoparathyroidism: Present and Future" (PDF). J. Clin. Endocrinol. Metab. 101 (6): 2313–24. doi:10.1210/jc.2015-3910. PMC 5393596. PMID 26938200.